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Abstract
In neutrophils, activation of the b2-adrenergic receptor (b2AR), a Gs-coupled receptor, inhibits inflammatory responses,
which could be therapeutically exploited. The aim of this study was to evaluate the effects of various b2AR ligands on
adenosine-39,59-cyclic monophosphate (cAMP) accumulation and N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-
induced superoxide anion (O2
N2) production in human neutrophils and to probe the concept of ligand-specific receptor
conformations (also referred to as functional selectivity or biased signaling) in a native cell system. This is an important
question because so far, evidence for functional selectivity has been predominantly obtained with recombinant systems,
due to the inherent difficulties to genetically manipulate human native cells. cAMP concentration was determined by HPLC/
tandem mass spectrometry, and O2
N2 formation was assessed by superoxide dismutase-inhibitable reduction of
ferricytochrome c. b2AR agonists were generally more potent in inhibiting fMLP-induced O2
N2 production than in
stimulating cAMP accumulation. (2)-Ephedrine and dichloroisoproterenol were devoid of any agonistic activity in the cAMP
assay, but partially inhibited fMLP-induced O2
N2 production. Moreover, (2)-adrenaline was equi-efficacious in both assays
whereas the efficacy of salbutamol was more than two-fold higher in the O2
N2 assay. Functional selectivity was visualized by
deviations of ligand potencies and efficacies from linear correlations for various parameters. We obtained no evidence for
involvement of protein kinase A in the inhibition of fMLP-induced O2
N2 production after b2AR-stimulation although cAMP-
increasing substances inhibited O2
N2 production. Taken together, our data corroborate the concept of ligand-specific
receptor conformations with unique signaling capabilities in native human cells and suggest that the b2AR inhibits O2
N2
production in a cAMP-independent manner.
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Introduction
Human neutrophils are crucial for the defense of the host
organism against infectious agents such as bacteria, fungi,
protozoa, viruses and tumor cells. After phagocytosis of invading
agents neutrophils are able to destruct them, the respiratory burst
NADPH oxidase being a major player [1]. This enzyme catalyzes
the univalent reduction of molecular oxygen (O2) to the
superoxide anion (O2
N2) with NADPH as electron donor [2–5].
Activation of neutrophils is triggered by bacterial formyl peptides
[6]. Upon binding of N-formyl-L-methionyl-L-leucyl-L-phenylal-
anine (fMLP) to the formyl peptide receptor, which is Gi-coupled
[7–8], O2
N2 production in neutrophils increases [1]. fMLP-
stimulated O2
N2 production in neutrophils is counteracted by
compounds that increase the intracellular adenosine-39,59-cyclic
monophosphate (cAMP) concentration [2]. These compounds
include prostaglandins, the inhibitor of phosphodiesterases, 3-
isobutyl-1-methylxanthine (IBMX), membrane-permeable analogs
of cAMP as well as agonists of the b2-adrenergic receptor (b2AR)
[9–14]. Furthermore, fMLP-stimulated O2
N2 formation is en-
hanced by the incubation of neutrophils with N-(2-{[(E)-3-(4-
bromophenyl)prop-2-enyl]amino}ethyl)isoquinoline-5-sulfon-
amide (H-89), an inhibitor of cAMP-dependent protein kinase
(PKA) [11]. Canonically, the b2AR couples to Gs proteins in order
to activate adenylyl cyclases (AC) resulting in increased intracel-
lular cAMP concentration [2]. Nevertheless, the b2AR can also
couple to Gi proteins, Gq proteins and b-arrestin, triggering
responses distinct from those activated through Gs proteins [15–
19].
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Classic models of G-protein-coupled receptor (GPCR) activa-
tion postulate the existence of a single active (R*) and an inactive
(R) state [20–22]. In the active R* state, the receptor is assumed to
activate its cognate G protein and regulate down-stream effectors.
However, over the past 15–20 years, compelling evidence from
various groups has accumulated that the R/R* dichotomy is too
simplicistic. These studies comprise biochemical, pharmacological
and biophysical approaches [19–39]. Accordingly, it is now
generally assumed that any given ligand stabilizes a ligand-specific
receptor conformation with unique signaling capabilities, resulting
in ligand-specific activation of G-proteins and/or b-arrestin
[27,28]. Stabilization of ligand-specific receptor conformations
with unique signaling capabilities is also referred to as functional
selectivity or biased signaling [20–22,29–33]. To this end, most of
the evidence for ligand-specific receptor conformations has been
obtained in studies with recombinant systems [34–36] or purified
receptor proteins [31,37–39], but studies on the relevance of
ligand-specific receptor conformations in native human cells are
still largely missing. Reasons for this lack of knowledge are
inherent difficulties to manipulate human cells genetically. In
addition, after isolation, human blood cells such as neutrophils
survive only for limited period of time [40]. However, since the
concept of functional selectivity implies that certain ligands can be
clinically more efficacious in a given setting while displaying less
unwanted effects, it is of paramount importance to probe
functional selectivity in native cells.
Recently, we have reported on the functional selectivity of
another Gs-coupled receptor, the histamine H2 receptor, in two
native cell systems, human eosinophils and neutrophils [40]. The
pharmacological profiles of H2R agonists as well as H2R
antagonists do not match by comparing their effects on eosinophils
and neutrophils as well as by comparing these parameters with
data obtained in a recombinant test system. Moreover, even in the
same cell type, differences were observed when ligands were
characterized determining two different parameters. Each ligand
triggers unique effects depending on the test system and
parameters measured which is of importance for further drug
development.
The aim of the present study was the characterization of the
b2AR on human neutrophils with a series of structurally diverse
b2AR ligands and thereby, to probe the concept of ligand-specific
receptor conformations on one of the most important and best-
characterized GPCRs in a physiologically relevant native human
cell system. Two distinct parameters were chosen for the
characterization of the b2AR on neutrophils. The first parameter
was measurement of the cAMP content in neutrophils. The second
parameter was monitoring of the b2AR-mediated effects on fMLP-
stimulated O2
N2 production. We also examined the effects of
various pharmacological tools including protein kinase inhibitors,
AC inhibitors and activators and various cAMP analogues on
fMLP-induced O2
N2 production in order to obtain further insights




4-yloxy)butan-2-ol) ((6)-(S*, S*)-ICI 118551) (ICI) and (6)-
bisoprolol (BIS) were obtained from Tocris Bioscience (Avon-
mouth, Bristol, UK). (2)-Isoproterenol (ISO), (2)-adrenaline
(ADR), (6)-salbutamol (SAL), (6)-dobutamine (DOB), (6)-
metoprolol (MET), (6)-alprenolol (ALP), (6)-atenolol (ATE)
and forskolin (FSK) were from Sigma-Aldrich (St. Louis, MO,
USA). (2)-Ephedrine (EPH) was from Mallinckrodt (St. Louis,
MO, USA) and (6)-dichlorisoproterenol (DCI) from Aldrich
(Milwaukee, WI, USA). Chemical structures of ligands are
depicted in Fig. S1. Stock solutions of ISO, ADR, SAL, DOB,
EPH and DCI (10 mM each) were prepared in 1 mM HCl and
stock solutions of ICI, MET, ALP, BIS and ATE in Millipore
water. Dilution series of all ligands were prepared in Millipore
water. Dulbecco’s PBS (DPBS, 10 x) without Ca2+ and Mg2+
(pH 6.5–7.0) was purchased from PAN Biotech (Aidenbach,
Germany) and Biocoll separating solution from Biochrom
(Berlin, Germany). Trypan blue solution, ferricytochrome c,
cytochalasin B, fMLP and IBMX were from Sigma-Aldrich.
Solvents for extraction and HPLC analysis were purchased as
follows: HPLC-gradient grade water and methanol from J. T.
Baker (Deventer, The Netherlands), ammonium acetate from
Sigma-Aldrich and acetic acid from Riedel-de Haen (Hannover-
Seelze, Germany). Tenofovir was obtained from the National
Table 1. Comparison of potencies and efficacies of standard b2AR agonists, determined in three different test systems.
Cpd.
O2
N2 assay (b2AR on neutrophil
granulocytes)
cAMP assay (b2AR on neutrophil
granulocytes)
GTPase assay (recombinant protein
hb2AR-GsaS)
pIC506 S.E.M.
(IC50 in mM) Emax 6 S.E.M.
pEC506 S.E.M.
(EC50 in mM) Emax6 S.E.M.
pEC506 S.E.M.
(EC50 in mM) Emax 6 S.E.M.
ISO 8.0260.07 (0.0096) 1.00 7.4260.10 (0.038) 1.00 7.50b (0.032) 1.00b,c
ADR 7.8260.09 (0.015) 1.0160.05 6.8160.09 (0.16) 1.0660.04 7.37c (0.043) 1.00c
SAL 7.1660.12 (0.069) 0.7760.04 6.7460.15 (0.18) 0.3560.03 6.70b (0.20) 0.74b
DOB n.d. 0.1560.03a 4.8660.36 (13.8) 0.2160.05 6.70b (0.20) 0.45b
EPH 5.9560.23 (1.12) 0.3460.04 ,4 (,100) 0.0160.01 4.69b (20.5) 0.31b
DCI 4.4060.26 (39.8) 0.3260.06 ,4 (,100) 0.0060.01 7.09b (0.082) 0.17b
On human neutrophil granulocytes, the O2
N2 assay (16105 cells per well) and the cAMP assay (56105 cells per cup) were performed as described under Materials and
Methods. Data were analyzed by non-linear regression and were best fitted to sigmoidal concentration/response curves. Data shown are the means of four to nine
independent experiments performed in triplicate. The efficacy (Emax) of ISO in each assay was set to 1.00 and the efficacies of other ligands were referred to this value.
n.d. not determined. As DOB at concentrations higher than 500 nM caused reduction of ferricytochrome c per se, the reliable determination of pIC50 value was not
possible. a Efficacy at concentration of 500 nM was taken as Emax.
b The data were taken from [45]. The reported non-logarithmic EC50 values were converted into
logarithmic pEC50 values.
c The data were taken from [43]. The non-logarithmic EC50 values shown in mM in parentheses were converted into logarithmic pEC50 value.
The literature data on GTPase assay are lacking S.E.M., because the original data are represented in non-logarithmic manner and/or S.D. or 95% confidence interval is
indicated instead of S.E.M. Therefore, calculation of S.E.M. from available data was impossible.
doi:10.1371/journal.pone.0064556.t001
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Institutes of Health (Bethesda, MD, USA). N6,29-O-dibutyryla-
denosine-39,59-cyclic monophosphate (DB-cAMP) (.96%; ,3%
monobutyryl derivatives; ,0.5% cAMP) was purchased from
Sigma-Aldrich. cAMP (.99.9%), adenosine-39,59-cyclic mono-
phosphorothioate, Rp-isomer (Rp-cAMPS) (.99.94%), N6-
monobutyryladenosine-39,59-cyclic monophosphate (6-MB-
cAMP) (.99.56%), 29-O-monobutyryladenosine-39,59-cyclic
monophosphate (29-O-MB-cAMP) (.99.69%), adenosine-39,59-
cyclic monophosphorothioate, Sp-isomer (Sp-cAMPS)
(.99.96%), and 8-(4-chlorophenylthio)-29-O-methyladenosine-
39,59-cyclic monophosphate (8-pCPT-29-O-Me-cAMP)
(.99.97%) were obtained from BIOLOG Life Science Institute
(Bremen, Germany). Structures of cAMP analogs are shown in
Fig. S2. Purities of cyclic nucleotides were determined by
HPLC. Stock solutions of nucleotides (100 mM each) were
prepared with Millipore water. H89 was obtained from Merck
(Darmstadt, Germany) as a 10 mM solution in DMSO.
KT5720 was from Enzo Life Sciences (Farmingdale, NY,
USA) and a 10 mM stock solution was prepared in DMSO. SQ
22536 (Merck, Darmstadt, Germany) was prepared as a 10 mM
solution in DMSO. FSK (10 mM) was dissolved in DMSO as
well. Phorbol-12-myristate-13-acetate was prepared as a 10 mM
solution in DMSO and was purchased from Sigma. Working
solutions of all named substances were prepared by diluting
stock solution with Millipore water.
Isolation of Human Neutrophils
This study and the consent procedure were approved by the
Ethics Committee of the Medical School of Hannover. Written
consent was obtained by all volunteers. The completed and
signed consent forms are kept on file in the secretary of the
Institute of Pharmacology of the Medical School of Hannover.
Human neutrophils were isolated from venous blood of healthy
volunteers of either sex (1.6 mg EDTA/ml blood as anticoag-
ulant) or from buffy coat obtained from the Institute for
Transfusion Medicine (Medical School of Hannover, Germany).
Buffy coat preparations were also obtained from individual
donors. All isolation steps were carried out at room tempera-
ture. Firstly, 7 ml of venous blood or 5 ml of buffy coat were
diluted to 35 ml with 16DPBS and carefully layered onto 15 ml
of Biocoll separating solution (density 1.077 g/ml) in a 50 ml-
Falcon tube. Following centrifugation (30 min, 4006g), the
upper three layers were removed. The residual pellet (,2 ml),
which contained erythrocytes and granulocytes, was resuspended
in 18 ml of Millipore water and incubated for 1 min under
gentle agitation in order to achieve selective lysis of erythro-
cytes. Afterwards, isotonicity was restored by adding 2.2 ml of
106DPBS, and centrifugation at 3006g for 5 min followed.
The lysis step was repeated once to remove residual erythro-
cytes. The cell pellet was re-suspended in 5 ml of 16DPBS and
sedimented by centrifugation at 3006g for 5 min. The resulting
cell preparation consisted of viable neutrophils (.98%), as
assessed by the trypan blue exclusion test. Finally, neutrophils
were suspended in 16PBS (16106 cells/ml for the O2
N2 assay
or 16107 cells/ml for the determination of cAMP) and stored
on ice until use. Experiments were performed within 4 h after
completion of isolation because at later time points, viability of
cells declined substantially as assessed by trypan blue dye uptake
and declined responsiveness to receptor ligands (data not
shown).
Superoxide Anion Generation (O2
N2 Assay)
Reactions were carried out in 96-well plates in triplicate.
Standard reaction mixtures (total volume 200 ml) contained 1 mM
CaCl2, 100 mM ferricytochrome c, 0.3 mg/ml cytochalasin B
(priming role by enhancing O2
N2 formation upon exposure to
fMLP) [2], ligands at different concentrations (where indicated,
additionally PKA inhibitors, AC inhibitors or cAMP analogs) and
16105 neutrophils in 16DPBS. After pre-incubation of the
reaction mixtures for 3 min at 37uC, reactions were initiated by
addition of fMLP (1 mM). Reference samples contained all
components listed above except for fMLP. O2
N2 formation was
continuously measured by monitoring the reduction of ferricyto-
chrome c at 550 nm for 30 min at 37uC, using a Synergy 4
microplate reader (BioTek Instruments, Winooski, VT, USA). The
difference in absorbance at 550 nm between 0 min (addition of
fMLP) and 30 min was used for subsequent data analysis, in order
to assess agonistic activity of examined ligands. With the exception
of DOB, all examined test compounds did neither reduce
ferricytochrome c nor stimulate O2
N2 production per se nor acted
as radical scavenger as assessed by the lack of effect on phorbol
ester-stimulated O2
N2 production (data not shown). As at DOB
concentrations higher than 500 nM, ferricytochrome c reduction
took place, the maximum concentration of DOB used in the O2
N2
assays was 500 nM.
Figure 1. Superoxide anion generation assay (O2
N2 assay). The
O2
N2 production in human neutrophil granulocytes (16105 cells per
well) was monitored by measuring the superoxide dismutase-inhibit-
able reduction of ferricytochrome c at 550 nm as described under
Materials and Methods. (A) Continuous measurement of O2
N2 produc-
tion for 30 min under control conditions (control), after stimulation with
1 mM fMLP (fMLP) and in the presence of 1 mM fMLP in combination
with 1 mM ISO (fMLP+ISO). Data shown are from one representative
experiment performed in triplicate. (B) Concentration-response curve
for ISO in the O2
N2 assay. Data shown are from nine independent
experiments, performed in triplicate (data points are means 6 S.E.M.).
Data were analyzed by non-linear regression and were best fitted to
sigmoidal concentration/response curve. (C) Inter-experimental vari-
ability of inhibitory effect of 1 mM ISO on fMLP-stimulated O2
N2
production. Each data point represents one independent experiment.
Increase in absorbance at 550 nm during 30 min after addition of fMLP
was set to 1.00 and increase in absorbance in the presence of 1 mM ISO
(+ fMLP) in each assay was compared to this value.
doi:10.1371/journal.pone.0064556.g001
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cAMP Accumulation and Extraction from Neutrophils
(cAMP Assay)
Reactions were conducted in triplicate in 1.5 ml Eppendorf
reaction vessels in a total volume of 100 ml. Fifty ml of the reaction
mixture containing CaCl2 (1 mM final concentration after
addition of neutrophils), IBMX (non-selective phosphodiesterase
inhibitor; 100 mM) and the respective ligand at different concen-
trations in 1 x DPBS were pre-incubated for 5 min at 37uC.
Isolated neutrophils suspended in 16DPBS were pre-incubated
separately for 10 min at 37uC. Following the addition of 50 ml of
neutrophils (56105 cells/reaction vessel) to reaction mixture,
samples were incubated for 10 min at 37uC. Afterwards, samples
were incubated for 10 min at 95uC in order to denature cell
proteins and then cooled to 4uC. One hundred ml of ice-cold
internal standard (tenofovir; 100 ng/ml) in eluent A (3/
97 MeOH/H2O, 50 mM NH4OAc, 0.1% HOAc) were added.
The suspension was centrifuged at 20.8006g at 4uC for 5 min in
order to remove denatured proteins. The cAMP concentration of
the supernatant was determined by reversed phase HPLC coupled
to mass spectrometry (HPLC-MS/MS).
Quantitation of cAMP by HPLC-MS/MS
In this study, cAMP levels were determined by HPLC-MS/
MS which is characterized by extremely high sensitivity and
specificity [41–42]. Since this method is not yet commonly
known and used, we describe the experimental protocol in some
detail. The chromatographic separation was performed on an
Agilent 1100 Series HPLC System (Agilent Technologies, Santa
Clara, CA, USA) equipped with a binary pump system and
with a 100 ml sample loop. A combination of Supelco Column
Saver (2.0 mm filter, Supelco Analytical, Bellafonte, CA, USA),
Security Guard Cartridge (C18, 462 mm) in an Analytical
Guard Holder KJO-4282 (Phenomenex, Aschaffenburg, Ger-
many) and an analytical Zorbax Eclipse XDB-C16 column
(5064.6 mm, 1.8 mm particle size, Agilent Technologies),
temperature controlled by a HPLC column oven at 25uC,
were used. The binary pump system supplied eluent A (50 mM
ammonium acetate and 0.1% (v/v) acetic acid in a methanol/
water mixture (3/97 (v/v)) and eluent B (50 mM ammonium
acetate and 0.1% (v/v) acetic acid in a methanol/water mixture
(97/3 (v/v)). The injection volume was 50 ml and the flow rate
of 0.4 ml/min remained constant throughout the chromato-
graphic run. From 0 to 5 min, the gradient of eluent B was
linearly increased from 0 to 50% of eluent B, and re-
equilibrium of the column to 100% of eluent A was achieved
from 5 to 8 min. Retention times of the analyte cAMP and the
internal standard tenofovir were 6.2 and 5.4 min, respectively.
The internal standard was used to mathematically correct the
loss of cAMP during preparation as well as possible variabilities
in HPLC-MS/MS measurement. Analyte detection was con-
ducted on an AB Sciex QTRAP 5500 triple quadrupole mass
spectrometer (AB Sciex, Foster City, CA, USA) using selected
reaction monitoring (SRM) analysis in positive ionization mode.
For this purpose nitrogen was used as collision gas. Using a
50 ms dwell time, SRM transitions were monitored as follows:
cAMP +330/136 and +330/312, tenofovir +288/176 and
+288/159. The transition +330/136 was the most intense
transition of cAMP and therefore used for quantification.
Additionally the +330/312 transition of cAMP was used as
qualifier. The transition +288/176 of tenofovir was used as
quantifier and the transition +288/159 as qualifier. The mass
spectrometer parameters were as follows: ion source voltage:
4500 V, ion source temperature: 600uC, curtain gas: 30 psi and
collision gas: 9 psi. cAMP in samples was quantified by applying
the standard curve, obtained by analysis of known amounts of
pure cAMP at: 0.0262, 0.066, 0.164, 0.41, 1.024, 2.56, 6.4, 16,
40, 100, 250 pmol/tube.
Miscellaneous (Data Analysis, Statistical Analysis and
GTPase Assay)
Chromatograms, obtained by the HPLC-MS/MS analysis,
were analyzed with the Analyst Software 1.5.1 (AB Sciex).
Steady-state GTPase activity assay, using membrane prepara-
tions of Sf9 insect cells, expressing fusion protein b2AR-GsaS,
was performed as described previously [43]. Data from the
O2
N2, cAMP and GTPase assays were analyzed with the Prism
5.01 software (GraphPad, San Diego, CA, USA). The means 6
S.E.M. were always determined by the analysis of at least three
Figure 2. Measurement of cAMP content in neutrophil granulocytes (cAMP assay). cAMP accumulation in human neutrophil granulocytes
(56105 cells per sample) was monitored by HPLC-MS/MS system as described under Materials and Methods. (A) Concentration-response curve for ISO
in the cAMP assay. Data shown are from four independent experiments, performed in triplicate (data points are mean 6 S.E.M.). The maximal ISO-
induced cAMP production was set to 1.00. Data were analyzed by non-linear regression and were best fitted to sigmoidal concentration/response
curve. (B) Inter-experimental variability of basal cAMP concentration in neutrophil granulocytes (basal) and cAMP level after stimulation with 1 mM
ISO (ISO 1 mM). Each data point represents one independent experiment. cAMP levels after stimulation with ISO increased by 30–1000% relative to
basal cAMP levels.
doi:10.1371/journal.pone.0064556.g002
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independent experiments, performed in triplicate, if not
indicated otherwise.
The efficacy (Emax) of ISO in each assay was set to 1.00 and the
efficacies of other ligands were referred to this value. The pKB
values for b2AR antagonists were calculated according to Cheng
and Prusoff [44] using the following equation: pKB= - log(IC50anta-
gonist/(1+(cISO/x))); IC50antagonist – IC50 value of an antagonist,
determined in antagonist mode, cISO – used concentration of ISO,
6– IC50 (O2
N2 assay) or EC50 value (cAMP assay and GTPase
assay) for ISO, determined in agonist mode (data from Table 1).
Data for receptor ligands were analyzed using one-way
ANOVA, followed by Bonferroni’s multiple comparison test, in
order to compare pKB values of the examined b2AR antagonists
between the O2
N2, cAMP and GTPase assay. Data for AC- and
PKA inhibitors were analyzed using one-way ANOVA, followed
by Dunnett’s multiple comparison test. Statistical significance was
defined as p , 0.05 (95% confidence interval).
Results
Characterization of the b2AR on Human Neutrophils with
b2AR Agonists
b2AR agonists with efficacies varying from very weak partial to
full agonism [45] were examined. The effects of b2AR agonists
were measured as inhibition of fMLP-stimulated O2
N2 production
(Fig. 1) and as cAMP accumulation (Fig. 2). In both cases, the
inter-experimental variability was high (Figs. 1 and 2). Note that in
Figs. 1C and 2B, data from different individuals are depicted.
High inter-individual variability of human neutrophil function was
observed previously [46]. However, when neutrophils from a given
donor were analyzed on different days, data in the two test systems
generally varied by less than 20% (data not shown). Thus,
interindividual data variability is a much greater issue with
neutrophils than intraindividual day-to-day variability. Accord-
ingly, in order to allow comparison of results from experiments
with different donors in this study, data were normalized with 1.00
representing the maximal effect of the b2AR agonist ISO and 0.00
representing the basal activity.
Potencies and efficacies of the examined b2AR agonists in the
O2
N2 and the cAMP assay are listed in Table 1 and concentration-
response curves are depicted in Fig. 3. Additionally, the EC50 and
Emax values of ligands determined in steady-state GTPase activity
assays using membrane preparations of Sf9 insect cells expressing
the b2AR-GsaS fusion protein [43,45] are listed in Table 1. The
b2AR-GsaS fusion protein is artificial but has become a standard
system for the pharmacological analysis of the b2AR [43,45]. For a
detailed discussion on the advantages and disadvantages of the
fusion protein technique as well as additional references relevant
for this approach, the reader is referred to ref. 43. Potencies of
ISO, ADR and SAL were higher in the O2
N2 assay than in the
cAMP assay. EPH and DCI were lacking agonistic activity in the
cAMP assay at concentrations up to 100 mM, whereas inhibitory
effects of both ligands on fMLP-stimulated O2
N2 production were
readily observed. The efficacy of ADR was comparable in both
test systems, but the efficacy of SAL more than two times higher in
the O2
N2 assay relative to the cAMP assay. When the data from
the recombinant test system were included in the comparison, the
rank order of potency of ligands was cAMP assay,GTPase
assay,O2
N2 assay, and the rank order of efficacy was cAMP
assay,O2
N2 assay < GTPase assay (Fig. 4).
In case of the two-state model postulating a single active state,
we would have expected linear correlations for agonists with
respect to efficacies and potencies, regardless of which parameters
are compared. However, Fig. 4 shows that the correlations are, in
general, rather poor, regardless of which comparisons are being
made. The worst correlations in terms of deviation from the
theoretically expected slope of 1.00 in case of identity of
parameters were observed for the comparison of pEC50 values
in the GTPase and O2
N2 assay (Fig. 4B) and pEC50 values in the
GTPase and cAMP assay (Fig. 4C). A limitation of our study is
that we studied only a limited number of agonists, but an
advantage is that the ligands cover a broad range of efficacies and
potencies so that clustering of the data in one spot is avoided. In
fact, this type of two-dimensional comparison of ligand potencies
and efficacies has been repeatedly used to support the concept of
ligand-specific receptor conformations in various test systems
[24,27,32,40].
A trivial explanation for the differing effects of b2AR agonists in
the O2
N2 assay and cAMP assay could be that the agonists exhibit
O2
N2 scavenging properties on fMLP-stimulated O2
N2 production.
However, when O2
N2 production in neutrophils was triggered with
phorbol-12-myristate-13-acetate (activator of protein kinase C,
Figure 3. Concentration-response curves for b2AR agonists
determined in the O2
N2 assay (A) and cAMP assay (B). The O2
N2
assay (16105 cells per well) and the cAMP assay (56105 cells per cup)
were performed as described in Materials and Methods. Data were
analyzed by non-linear regression and were best fitted to sigmoidal
concentration/response curves. Data shown are the means 6 S.E.M. of
four to nine independent experiments performed in triplicate. As DOB
at concentrations higher than 500 nM caused reduction of ferricyto-
chrome c per se, the maximal DOB concentration examined in the O2
N2
assay was 500 nM.
doi:10.1371/journal.pone.0064556.g003
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100 nM) instead of fMLP, the examined b2AR agonists had no
effect on O2
N2 production at all (data not shown).
Characterization of the b2AR on Human Neutrophils with
b2AR Antagonists
According to conventional models of GPCR activation, potency
of an antagonist for a given receptor is constant irrespective of the
tissue or recombinant system selected for the characterization, the
agonist used for the stimulation of GPCR and downstream
signaling event monitored [20–22,47]. However, by monitoring
the cAMP accumulation and cAMP response element-mediated
reporter gene transcription in Chinese hamster ovary (CHO) cells,
different KB values were determined for b2AR antagonists [48].
These data indicate that antagonists, like agonists, may stabilize
functionally distinct receptor conformations. Likewise, we ob-
tained evidence for functional selectivity of antagonists at various
recombinant histamine receptor subtypes [49]. Hence, the
question arose whether parameter-dependent b2AR antagonist
potency is also apparent in a native test system, namely in
neutrophils.
The pKB values for ICI, MET, ALP, BIS and ATE were
determined in the cAMP and O2
N2 assay by applying a
submaximally effective concentration of ISO and increasing
concentrations of b2AR antagonists. Concentration-response
curves for antagonists are shown in Fig. 5. In Table 2, the results
are summarized and compared with antagonistic activity of the
same ligands in the recombinant test system (GTPase assay using
membranes of Sf9 insect cells expressing b2AR-GsaS). The
statistical analysis of the obtained data revealed no difference of
pKB values between the two different parameters in neutrophils,
BIS being an exception. However, in comparison with data on
neutrophils, the potencies of all antagonists were significantly
reduced on the recombinantly expressed b2AR-GsaS. Fig. 6 shows
correlations of the pKB values of antagonists for the various
parameters analyzed. It is evident that the correlations for
antagonists are much better than the corresponding correlations
for agonists shown in Fig. 5.
Do AC- and PKA-activation Interfere with fMLP-
stimulated O2
N2 Production?
As already mentioned in the introduction, b2AR-signaling is
very complex, depending on ligand and test system
[15,16,18,26,27]. b2AR-mediated inhibition of fMLP-stimulated
O2
N2 production is thought to be due to cAMP production and
PKA activation [50–51]. In order to address this question we
studied the effects of three structurally distinct and well-established
PKA inhibitors. Among the inhibitors are an isoquinoline
sulfonamide [52], a cAMP analog [53] and a microbial metabolite
[54]. However, in our experiments, we failed to obtain evidence
for the hypothesis that activation of PKA after b2AR stimulation is
a crucial event for inhibition of fMLP-stimulated O2
N2 production
(Fig. 7). Specifically, compounds H89 and KT5720, widely-used
and effective cell-permeable competitive inhibitors of the ATP-
binding to the ATP-binding pocket of the PKA in other test
systems [55–58], did not reverse ISO-induced inhibition of fMLP-
stimulated O2
N2 production (also when neutrophils were pretreat-
ed 15 min with H89 or KT5720). Even the cAMP antagonist Rp-
cAMPS which competes with cAMP for the binding to the
regulatory subunits of PKA [57,59], did not interfere with the
effect of ISO of O2
N2 production in human neutrophils (Fig. 7).
Moreover, we tried to assess the involvement of the cAMP
signaling pathway in the fMLP-stimulated O2
N2 production by
applying the AC inhibitor SQ 22536 [60]. Surprisingly, SQ 22536
enhanced rather than diminished the inhibitory effect of ISO on
fMLP-induced O2
N2 production (Fig. 8A). Additionally, SQ 22536
exhibited unexpected inhibitory effects on fMLP-induced O2
N2
production on its own. SQ 22536 by itself did not increase cAMP
levels in neutrophils, and the compound also did not inhibit the
ISO-induced cAMP increase (Fig. 8B). Pleiotropic and AC-
Figure 4. Pair-wise comparison of the potencies (A–C) and efficacies (D–F) of the b2AR agonists in the O2
N2 assay, the cAMP assay
and the GTPase assay. The data for comparison were taken from Table 1 and were analyzed by linear regression. The dashed lines represent the
95% confidence intervals in the regression line. The diagonal dotted line indicates a theoretical line for identical values (slope = 1). Slopes (95%
confidence interval) and r2 of the calculated correlations are as follows; A. 1.02 (0.22 to 1.81), 0.85; B. 0.27 (21.05 to 1.58), 0.12; C. 0.42 (20.32 to
1.15), 0.38; D. 1.04 (20.14 to 2.21), 0.73; E. 0.83 (0.02 to 1.63), 0.78; F. 0.72 (0.22 to 1.22), 0.89.
doi:10.1371/journal.pone.0064556.g004
Table 2. Comparison of pKB values of the b2AR antagonists, determined in three different test systems.
Cpd.
O2
N2 assay (b2AR on neutrophil
granulocytes)
cAMP assay (b2AR on neutrophil
granulocytes)
GTPase assay (recombinant protein
b2AR-GsaS)
a
pKB 6 S.E.M. (KB in mM) pKB 6 S.E.M. (KB in mM) pKB 6 S.E.M. (KB in mM)
ICI 9.5160.09 (0.00031) 9.9760.07 (0.00011) 8.5560.14***,+++ (0.0028)
MET 7.1860.15 (0.066) 7.1960.12 (0.065) 6.0860.17**,++ (0.83)
ALP 9.4060.10 (0.00040) 9.7160.06 (0.00020) 8.5660.14***,+++ (0.0028)
BIS 6.5860.19 (0.26) 7.1760.11* (0.068) 5.7760.10**,+++ (1.70)
ATE 5.8960.12 (1.29) 5.9960.20 (1.02) 5.1260.17*,+ (7.59)
On human neutrophil granulocytes, the O2
N2 assay (16105 cells per well) and the cAMP assay (56105 cells per sample) were performed as described under Materials and
Methods. Steady-state GTPase activity assay, using membrane preparations of Sf9 insect cells, expressing fusion protein b2AR-GsaS, was performed as described in [43].
O2
N2 and cAMP production as well as GTP hydrolysis were determined at submaximally effective concentration of ISO (100 nM in the O2
N2 and cAMP assay, 10 nM in the
GTPase assay) in the presence of increasing concentrations of b2AR antagonists. Data were analyzed by non-linear regression and were best fitted to sigmoidal
concentration/response curves. Data shown are from four to five independent experiments performed in triplicate. The pKB values were calculated from the IC50 values
according to Cheng and Prusoff [44]. pKB values were compared with each other using one-way ANOVA, followed by Bonferroni’s multiple comparison test (pKB
significantly different to: *O2
N2 assay, +cAMP assay; one symbol: p,0.05, two symbols: p,0.01, three symbols: p,0.001). Non-logarithmic KB values in mM are shown in
parentheses.
doi:10.1371/journal.pone.0064556.t002
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independent effects of SQ 22536 have been observed repeatedly
[61].
As an additional tool we examined the diterpene, FSK, a direct
activator of membranous ACs [61]. However, FSK did neither
significantly reduce fMLP-stimulated O2
N- production (Fig. 8A) nor
robustly increase cAMP levels (Fig. 8B).
In order to provide proof of principle that an increase in
intracellular cAMP concentration is capable of inhibiting fMLP-
stimulated O2
N2 production, we examined the effects of cAMP and
various cAMP analogs on NADPH oxidase activation. DB-cAMP
is lipophilic and penetrates the plasma membrane. Inside the cell,
DB-cAMP is converted to the biologically active 6-MB-cAMP
[62]. In accordance with previous data [9], DB-cAMP reduced
fMLP-stimulated O2
N2 production, whereas the control compound
sodium butyrate was ineffective (Fig. 9). In addition, the mono-
butyrylated control compound 6-MB-cAMP did not robustly
inhibit NADPH oxidase, most likely due to inefficient membrane
penetration. Sp-cAMPS is less lipophilic than DB-cAMP but does
not require bioactivation [59]. Sp-cAMPS was similarly effective at
inhibiting O2
N2 production as DB-cAMP. These data show that
cAMP does have the potential to inhibit NADPH oxidase.
However, we also noted that very high concentrations of DB-
cAMP are required to elicit inhibition, probably exceeding the
intracellular cAMP concentrations achieved following b2AR
stimulation.
cAMP itself also slightly inhibited O2
N2 production. This could
be due to extracellular degradation of cAMP to adenosine by
phosphodiesterases and ectonucleotidases and subsequent activa-
tion of adenosine A2-receptors by adenosine [63]. Import of
cAMP via multidrug resistance protein transporters (MRPs) into
cells and subsequent PKA activation could be involved as well
[64]. Likewise, the small inhibitory effects of the PKA inhibitor
Rp-cAMPS could be due to adenosine liberation from the parent
compound. We do not have a satisfactory explanation for the small
but significant stimulatory effect of the mono-butyrylated control
compound 29-O-MB-cAMP on O2
N2 production. However, we
confirmed that the compound per se did not activate O2
N2
production or reduced ferricytochrome c independently of
NADPH oxidase (data not shown). The activator of the cAMP
effector protein Epac, 8-pCPT-29-O-Me-cAMP [65], did not
inhibit fMLP-induced O2
N2 production, arguing against an
involvement of Epac in NADPH oxidase regulation. We also
observed that the PKA inhibitors H89, KT5720 and Rp-cAMPS
showed no reversing effect on the inhibition of O2
N2 production
caused by DB-cAMP (Fig. 7). These data raise questions whether a
hitherto unidentified cAMP-binding protein is involved in the
inhibition of O2
N2 production by DB-cAMP and Sp-cAMPS.
Discussion
The two-state model of receptor activation implying an active
(R*) and an inactive (R) state has now been superseded by a more
complex model involving multiple active receptor conformations
that lead to ligand-specific receptor activation, also referred to as
functional selectivity or biased agonism [19–33]. Functional
selectivity has been reported for numerous GPCRs such as
dopamine D1 and D2 receptors, the histamine H2 and H4
receptor, adenosine A1 and A3 receptors, the a2A-adrenoceptor
and the b2AR [15–33,40,49]. So-called biased ligands can
differently activate G protein-dependent and -independent signal-
ing such as the b-arrestin pathway [27,32,34,35], can discriminate
between Gs, Gi, Gq and other G protein-mediated pathways
[15,66] or even selectively modulate e.g. Gi1, Gi2 and Gi3 protein
subtype activities [67]. Therefore, it is not surprising that any
given ligand possesses multiple potencies and efficacies depending
on the down-stream pathway analyzed [33]. This concept was also
confirmed in our study with b2AR agonists in human neutrophils
using the cAMP assay and the O2
N2 assay as parameters and by
comparison of the results with literature data obtained in
recombinant test system (Fig. 4). If only a single active b2AR
conformation existed, we would have expected linear correlations
following the dotted lines in Fig. 4 between potencies and efficacies
(relative to the reference compound ISO) of agonists, regardless of
which parameters are considered. However, this was not the case.
In accordance with our data, fluorescence studies with purified
b2AR nuclear magnetic resonance studies provided evidence for
ligand-specific conformations [31,37,39].
With respect to b2AR antagonists, effects were similar in the
cAMP and O2
N2 assay on neutrophils (Table 2 and Fig. 5),
indicating that in neutrophils, functional selectivity is predomi-
nantly observed for b2AR agonists. In contrast to neutrophil
parameters, potencies of antagonists were generally lower at the
Figure 5. Concentration-response curves for b2AR antagonists determined in the O2
N2 (A), cAMP (B) and GTPase assay (C). The O2
N2
assay (16105 cells per well) and the cAMP assay (56105 cells per cup) were performed as described in sections 2.3 and 2.4, respectively. Steady-state
GTPase activity assay, using membrane preparations of Sf9 insect cells, expressing fusion protein b2AR-GsaS, was performed as described in [43]. Data
were analyzed by non-linear regression and were best fitted to sigmoidal concentration/response curves. Data shown are the means 6 S.E.M. of four
to five independent experiments performed in triplicate. O2
N2 and cAMP production as well as GTP hydrolysis were determined at submaximally
effective concentration of ISO (100 nM in the O2
N2 and cAMP assay, 10 nM in the GTPase assay) in the presence of increasing concentrations of b2AR
antagonists.
doi:10.1371/journal.pone.0064556.g005
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recombinant b2AR than at the native b2AR (Table 2), and there
were also ligand-specific differences. The trend towards lower
antagonist (inverse agonist) potencies at the recombinant b2AR
could be due to higher constitutive activity of the recombinant
than of the native system [20].
The vast majority of reports about functional selectivity
originate from studies with recombinant test systems or purified
receptors (see, e.g., [31,34–36,38–39]). On the contrary, functional
selectivity in native test systems has been rarely studied so far, e.g.
for the histamine H4 receptor on isolated human eosinophils [68]
and for the histamine H2 receptor on isolated human eosinophils
and neutrophils [40]. Here, we report on functional selectivity of
the b2AR in human neutrophils. In accordance with our data,
there is evidence for functional selectivity of b2AR ligands in
cardiomyocytes [69]. In this system, stereoisomers of fenoterol
differentially activate Gi- and Gs-proteins.
Unfortunately, in-depth analysis of functional selectivity in
neutrophils is hampered by limited possibilities to block coupling
of the b2AR to coupling partners. GPCR-Gi protein coupling can
be interrupted with pertussis toxin [70], whereas there is no
pharmacological tool available for the selective inhibition of Gs
and Gq coupling or the b-arrestin pathway in native test systems.
Furthermore, since the formyl peptide receptor is coupled to Gi-
proteins and an essential stimulatory component in the O2
N2 assay,
we could not use pertussis toxin to differentiate between b2AR
ligands in this assay and in the cAMP assay. Moreover, in
neutrophils, difficulties for effective genetic manipulation, inter-
individual variability and relatively short life time impede with
more detailed analysis of functional selectivity in this native test
system.
Our data obtained by measuring GTP hydrolysis in the
recombinant test system reflect coupling of the b2AR solely to
the short splice variant of the Gs protein [43,45]. There is no
Figure 6. Pair-wise comparison of the pKB values of the b2AR antagonists in the O2
N2 assay, the cAMP assay and the GTPase assay.
The data for comparison were taken from Table 2 and were analyzed by linear regression. The dashed lines represent the 95% confidence intervals in
the regression line. The diagonal dotted line indicates a theoretical line for identical values (slope = 1). Slopes (95% confidence interval) and r2 of the
calculated correlations are as follows; A. 1.05 (0.79 to 1.30), 0.98; B. 0.98 (0.84 to 1.12), 0.99; C. 0.93 (0.73 to 1.12), 0.99.
doi:10.1371/journal.pone.0064556.g006
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doubt that the b2AR couples to Gs in neutrophils, but no
information is available regarding the involvement of specific Gs
splice variants. The question remains what the reason for the
generally increased potency of the examined b2AR agonists in the
O2
N2 assay compared to the cAMP assay is. Lack of correlation
between the cAMP accumulation and inhibition of fMLP-induced
O2
N2 production in neutrophils has been described also by other
research groups using other stimuli [71–74]. Among other reasons,
better coupling efficiency of the b2AR to the O2
N2 pathway than to
the cAMP pathway is of relevance for the divergence in data.
Differences in strength of coupling to different signaling pathways
have been reported for other receptors [75]. Additionally, we have
no evidence for the involvement of Epac in the signal transduction
pathway of the b2AR leading to inhibition of NADPH oxidase
since an effective Epac activator failed to inhibit fMLP-stimulated
O2
N2 production (Fig. 9).
We failed to support an involvement of AC, cAMP and PKA in
b2AR-mediated inhibition of fMLP-stimulated O2
N2 production.
Thus, it appears that the two measured events (cAMP accumu-
lation and O2
N2 production) in neutrophils are independent of
each other. The lack of effect of DCI and EPH on cAMP
accumulation despite inhibitory effects of these ligands on O2
N2
production supports the concept of cAMP-independent inhibition
of NADPH oxidase. Moreover, SAL is more effective at inhibiting
NADPH oxidase than at increasing cAMP. Our failure to detect
stimulatory effects of DCI and EPH on cAMP accumulation and
ineffective stimulation of cAMP accumulation by SAL are not due
to cAMP degradation since we included a phosphodiesterase
inhibitor into the cAMP assay. Moreover, we applied a highly
sensitive and specific MS method to detect cAMP, avoiding
notorious cross-reactivity problems of antibodies widely applied in
cyclic nucleotide detection [41,42,76]. Thus, our study addressing
ligand-specific receptor conformations also casted doubt about the
dogma of cAMP-dependent inhibition of NADPH oxidase by the
b2AR although, in principle, cAMP can inhibit O2
N2 production
(Fig. 9). Even in case of inhibition of O2
N2 production by cAMP
analogs, we failed to obtain positive evidence for an involvement of
PKA (Fig. 7).
Analysis of the signaling pathways responsible for inhibition of
O2
N2 production in neutrophils is hampered by unsuitability of
Figure 7. Effects of different PKA inhibitors on the ISO- and DB-
cAMP-induced inhibition of fMLP-stimulated O2
N2 production.
O2
N2 production in human neutrophil granulocytes (16105 cells per
well) was monitored by measuring the superoxide dismutase-inhibit-
able reduction of ferricytochrome c at 550 nm. Data shown (mean 6
S.E.M.) are from three independent experiments, performed in triplicate.
Concentrations used are as follows; ISO 100 nM, DB-cAMP 500 mM, H89
1 mM, KT5720 10 mM and Rp-cAMPS 100 mM. H89, KT5720 and Rp-
cAMPS had no significant reversal effect on the inhibitions caused by
ISO and DB-cAMP.
doi:10.1371/journal.pone.0064556.g007
Figure 8. Effects of SQ 22536 and FSK on the fMLP-stimulated O2
N2 production (A) and cAMP accumulation (B). The O2
N2 assay (16105
cells per well) and the cAMP assay (56105 cells per cup) were performed as described in Materials and Methods. Data shown (mean6 S.E.M.) are from
three to six independent experiments, performed in triplicate. Concentrations used are as follows; ISO 100 nM (A) and 1 mM (B), SQ 22536 100 mM.
For comparison, we also studied the effect of the direct AC activator FSK (10 mM). In all tubes, a final concentration of 1% (v/v) DMSO (unavoidable for
dissolving SQ 22536 and FSK) was present to achieve comparable results. SQ 22536 had no significant reversal effect on the inhibition caused by ISO
in the O2
N2 assay, and FSK had no significant inhibitory effect on fMLP stimulation in this assay.
doi:10.1371/journal.pone.0064556.g008
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experimental tools available. Most strikingly, the widely used AC
inhibitor SQ 22536 failed to reduce the stimulatory effect of ISO
on cAMP levels but further augmented the inhibitory effect of ISO
on O2
N2 production (Fig. 8). Non-specific and pleiotropic effects of
SQ 22536 have been subject of a recent review [61]. Quite
striking too was the lack of inhibitory effect of FSK on O2
N2
production and lack of stimulatory effect of FSK on cAMP
production (Fig. 8). These data could be explained by a model
according to which the FSK-insensitive AC isoform 9 [61] is the
functionally predominant AC in neutrophils. This hypothesis
needs to be tested in future studies. Again, this is not a trivial task
since the quality of AC antibodies is generally poor [61], and we
are not aware of the availability of specific AC9 antibodies.
Stimulation of cAMP accumulation and reduction of O2
N2
production mediated by ISO, was inhibited according to
monophasic competition isotherms by ICI, a highly potent and
selective b2AR antagonist with very low potency on the b1-
adrenergic receptor [77]. In case of an exclusive involvement of
the b1-adrenergic receptor we would have expected low potency of
ICI, and in case of an involvement of both b-adrenergic receptors,
we would have expected biphasic isotherms. This was clearly not
the case (Fig. 5), and moreover, the potency of ICI at the native
b2AR was even higher than at the recombinant b2AR (Fig. 5 and
Table 2). Thus, the data obtained with ICI provide strong
evidence for the notion that only the b2AR but not the b1-
adrenergic receptor is functionally expressed in human neutro-
phils. Moreover, we excluded the possibility that ISO as
representative b2AR agonist cross-reacts with the histamine H2
receptor, which is also expressed on human neutrophils [40].
Specifically, the effect of ISO on fMLP-induced O2
N2 production
was not reduced by the histamine H2 receptor antagonists
famotidine, tiotidine and zolantidine (data not shown).
Stallaert and coworkers [78] demonstrated on HEK293S cells
that b2AR-dependent impedance response to ISO is the result of
activation of multiple signaling pathways, including Gs and Gi
coupling, Gbc-dependent signaling, cAMP production, extracel-
lular signal-regulated kinase (ERK) 1/2 activation as well as Ca2+
mobilization. Therefore, when stimulation of the b2AR does not
activate the PKA-dependent pathway in human neutrophils or this
pathway does not interfere with the NADPH oxidase signaling,
modulation of the e.g. ERK1/2-pathway could be the explanation
for the inhibition of the NADPH oxidase. Interestingly, in other
studies on human neutrophils, a correlation between activation of
cAMP/PKA signaling pathway and inhibition of ERK phosphor-
ylation was observed, resulting in reduced fMLP-induced O2
N2
production [79,80]. Intriguingly, the b2AR was reported to
activate ERK signaling pathway via interaction with Gi, Src
and/or arrestin proteins in addition to Gs proteins in other systems
[81]. As it is evident that b2AR-signalling strongly depends on the
cell system used [16], there is a need to address the correlation
between b2AR activation, ERK activation and fMLP-stimulated
O2
N2 production in future studies as well. This could provide an
explanation for the observed biased effects of some examined
b2AR ligands on neutrophils.
In preliminary studies we examined a number of pharmaco-
logical inhibitors to explore alternative signaling pathways of the
b2AR; e.g. we tested the p38 inhibitor SB203580, the JNK
inhibitors SP600125 and SP600123, the ERK inhibitor
PD980598, the PI3 kinase inhibitor LY294002 and the protein
kinase C inhibitor Goe 6978. Unfortunately, these compounds per
se inhibited fMLP-stimulated O2
N2 production (data not shown) so
that separate effects of these compounds on ISO actions could not
be properly dissected. An alternative approach will be the
examination of the effects of b2AR ligands on protein phosphor-
ylation in neutrophils, using screening approaches encompassing
numerous protein kinases as starting point. Lastly, it will also be
very important to explore the possibility that the new signaling
Figure 9. Effects of cAMP, butyrate and cAMP analogs on fMLP-stimulated O2
N2 production. O2
N2 production in human neutrophil
granulocytes (16105 cells per well) was monitored by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c at 550 nm as
described in Materials and Methods. Data shown (mean 6 S.E.M.) are from three to seven independent experiments, performed in triplicate. Data
were analyzed for statistical significance relative to the control (-, set to 1.0) using one-way ANOVA, followed by Dunnett’s multiple comparison test
(***p,0.001).
doi:10.1371/journal.pone.0064556.g009
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molecules cyclic CMP (cCMP) and cyclic UMP (cUMP) [82] are
involved in b2AR-mediated signal transduction.
Data from the literature suggest a feasible use of b2AR agonists
as anti-inflammatory agents [10,83]. In order to extend the data
on functional selectivity in native test systems, we compared the
effect of b2AR ligands on cAMP accumulation and O2
N2
production in human neutrophils. However, there are many
native test systems described, which would afford an expansion of
our knowledge about functional selectivity of b2AR ligands. One
example could be the parallel measurement of cAMP concentra-
tion and contractility of cardiomyocytes or endothelial cells as
functional parameter [16,69]. Moreover, a comparison of cAMP
accumulation and ERK phosphorylation in e.g. mouse embryonic
fibroblasts [84] could be used for screening of b2AR ligands. All in
all, there is a need to assess biased signaling through the b2AR in a
wide spectrum of native test systems in order to improve the
desired therapeutic effect of developed compounds on the one and
to minimize side effects on the other. Furthermore, b2AR agonists
that have been used for many years in the therapy of humans, e.g.
as bronchodilators in patients with asthma or chronic obstructive
pulmonary disease, should be reassessed using various native test
systems, as there is a potential to improve already existing
therapies, particularly by minimizing unwanted effects.
As a general approach to study functional selectivity in native
cells, it is necessary to construct a systematic data matrix in which
multiple ligands are examined at multiple concentrations (enabling
determination of precise potencies and efficacies) and for multiple
parameters. Previous studies with native human cells may have
largely overlooked functional selectivity at GPCRs because there
was no appreciation of the necessity to generate such a systematic
data collection in order to understand cell biology. It is evident
that availability of human cells is an issue for comprehensive
pharmacological studies. The human neutrophil, despite its
inherent problems, i.e. short survival time after isolation, variable
responsiveness and poor accessibility to genetic manipulation, is a
suitable model system to test functional selectivity for several
reasons. Specifically, neutrophils can be obtained in large
quantities, express multiple receptors, display numerous cell
functions that can be assessed quantitatively and are pathophy-
siologically relevant for inflammation.
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